It's been hailed as a miracle cure for hepatitis C – but comes with a billion-dollar price tag.
Commonwealth government is under pressure to subsidise Sovaldi,
produced by drug company Gilead, that has been approved by the
Therapeutic Goods Administration but has been rejected for listing on
the Pharmaceutical Benefits Scheme on value-for-money grounds.
Pharmaceutical Benefits Advisory Committee, the independent expert body
that decides which drugs should be subsidised, will consider a second
application to list the drug at its March meeting, along with
applications to list three other new hepatitis treatments.
Labels: access to treatment, australia, drug costs, Pharmaceutical Benefits Scheme (PBS), Sovaldi